|Bid||7.83 x 1400|
|Ask||8.15 x 900|
|Day's range||7.80 - 8.25|
|52-week range||7.37 - 94.17|
|Beta (5Y monthly)||N/A|
|PE ratio (TTM)||25.83|
|Forward dividend & yield||N/A (N/A)|
|1y target est||N/A|
Investors need to pay close attention to Atea (AVIR) stock based on the movements in the options market lately.
Atea (AVIR) stock falls on termination of collaboration with Roche for the development of oral drug for the treatment of COVID-19.
Shares of Atea Pharmaceuticals (NASDAQ: AVIR) fell by as much as 14.4% in premarket trading Wednesday morning. The biotech's shares are sliding today in response to Roche's (OTC: RHHBY) decision to terminate its involvement in the development of the oral COVID-19 therapy known as AT-527. Atea Pharmaceuticals will reportedly regain full commercial rights to the drug on Feb. 10, 2022.